Get to know what's happening behind the scenes.

Learn more



Read the latest on our blog. Let's Talk Innovation.


Stay connected with us on social media.

twitter_logo_20px.jpg @JNJinnovation


Press Releases

Read our latest news.

  • Johnson & Johnson Innovation’s global pursuit of cutting-edge science yields 15 new collaborations, pushing the total above 300.

    Collaborations advance novel research across pharmaceutical, medical device and consumer healthcare sectors, in areas including 3D printing, the microbiome and immunotherapy

    NEW BRUNSWICK, Jan. 5, 2017 — Johnson & Johnson Innovation LLC today announced 15 new collaborations spanning promising scientific areas, including 3D printing, the microbiome and immunotherapy. These collaborations, which are focused on developing novel healthcare solutions in areas of high unmet need such as depression, cancer and diabetes, bring the total number of strategic transactions to more than 300 since the establishment of Johnson & Johnson Innovation.

    Download the PDF for the full press release.

  • BlackThorn Therapeutics Secures $14 Million in Series A Extension Financing

  • eTheRNA joins the JLINX Community

    December 23, 2016

    Founded in January 2013 as a spin-off of the VUB Laboratory for Molecular and Cellular Therapy (LMCT) headed by Prof K. Thielemans, eTheRNA immunotherapies (Belgium) is a ground-breaking global pioneer in the development of mRNA-based immunotherapies for different cancers and certain infectious diseases.

    eTheRNA is focusing on therapies that prepare and activate the immune system by programming dendritic cells (DC) with synthetic mRNA. For this purpose, eTheRNA continues to develop its proprietary TriMix platform comprising three mRNA molecules that jointly have a boost effect on the activation and maturation of dendritic cells, leading to potent population of both helper T-cells and cytotoxic T-cells. 



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.